[Therapeutic effectiveness and tolerability of p-isobutylphenylpropionate of lysine, in parenteral administration, in subjects with hyperalgic forms of rheumatic arthropathy].
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001416:Back Pain / Q000188:drug therapy; D020968:Brachial Plexus Neuritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007592:Joint Diseases / Q000188:drug therapy; D008239:Lysine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010166:Palliative Care; D012585:Sciatica / Q000188:drug therapy; D013122:Spinal Diseases / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D008239:Lysine; C016106:solufenum; D007052:Ibuprofen
Efficacia terapeutica e tollerabilità del p-isobutilfenilpropionato di lisina, somministrato per via parenterale, in soggetti con forme iperalgiche di reumoartropatie.